About Shire UK
UK is an indirect wholly owned subsidiary of Shire plc, a global specialty
biopharmaceutical company that works closely with specialist physicians, nurses,
pharmacists and other healthcare professionals to develop and market medicines
that improve quality of life for patients, their families and carers.
Shire traces its history back to 1986, when a team of entrepreneurs began to
capitalize on a number of unmet medical needs. Within its first two years of
operation the UK-based specialty pharmaceutical company had launched a range of
supplemental calcium products for patients seeking to treat or prevent
osteoporosis. Soon thereafter innovative drug development programs were under
way on behalf of patients facing such challenging conditions as Alzheimer’s and
end-stage renal failure.
The UK operation now comprises this original product range, additional
speciality pharmaceuticals as well as therapies for genetic disorders.
Through the commitment of our
employees, we are aiming to make a difference to patients, their families
and carers, as well as to the medical community.
For information about Shire’s commitment to Transparency and adherence to the
Association of British Pharmaceutical Industry (ABPI) Code of Practice, please
visit Shire’s global corporate website
West Lancashire CCG and Shire Pharmaceuticals Limited
Joint Working Project Executive Summary
West Lancashire CCG and Shire Pharmaceuticals Limited are engaged in Joint
Working to help to develop a new multi discipline approach to West Lancashire
CCG’s commissioning of ADHD services Both parties have committed resources to
support this project, which will run from June 2017 – November 2017.
The objective of this Joint Working project is to work towards the delivery
of an all age mental health service for the people of West Lancashire. In
particular the CCG is reviewing the specification and commissioning of services
related to Attention Deficit Hyper Activity Disorder (ADHD).
Designed to support:
- Patient choice (setting, information, type of care, resources)
- Reduced waiting times
- Ensuring patients have an opportunity to set their own goals and that their views are respected
- Self-care and self-management
- More effective shared care
- More effective cross functional working both within the NHS and with other agency partners
- Training for relevant medical and none medical practitioners, especially on the use of appropriate, effective, and well tolerated medicines.
For further information please contact:
Shire UK - Phil Anderton 07710 919868,